Mesiproc

Clopidogrel, the active ingredient in Mesiproc, is an antiplatelet agent presented as an oral tablet for oral use. It helps prevent atherothrombotic events in patients with acute coronary syndrome, myocardial infarction, ischemic stroke or peripheral arterial disease. GNH USA supplies Mesiproc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesiproc, a P2Y12 receptor antagonist, is employed in several cardiovascular and cerebrovascular conditions. - Acute coronary syndrome: reduces the risk of recurrent myocardial infarction and death. - Post‑myocardial infarction (secondary prevention): lowers incidence of further cardiac events. - Ischemic stroke or transient ischemic attack: prevents recurrent stroke. - Peripheral arterial disease: diminishes limb‑related ischemic complications.

Clopidogrel may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bleeding gums - Easy bruising - Nausea - Diarrhea - Headache - Dizziness

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Thrombotic thrombocytopenic purpura - Significant liver enzyme elevation - Allergic reactions including anaphylaxis

When prescribing Mesiproc, clinicians should consider several safety measures. - Bleeding risk: evaluate patient history of hemorrhage before initiation. - Surgical procedures: discontinue according to peri‑operative guidelines. - Renal impairment: monitor renal function and adjust therapy as needed. - Concomitant anticoagulants: be aware of additive bleeding risk. - Drug hypersensitivity: avoid in patients with known clopidogrel allergy. - Store at ambient temperature: keep in original container, protect from moisture.

Clopidogrel interacts with several drug classes that may modify its antiplatelet effect or increase bleeding.

Major Interactions (Avoid): - Warfarin: synergistic increase in bleeding risk. - NSAIDs (e.g., ibuprofen, naproxen): heightened hemorrhage potential. - SSRIs or SNRIs: additive bleeding tendency.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (omeprazole, esomeprazole): may reduce clopidogrel activation. - CYP2C19 inhibitors (fluconazole, ticagrelor): alter metabolic conversion. - ACE inhibitors: monitor renal function and electrolytes.